Market Place
Sourcing Support
Twist Bioscience Enters Royalty Purchase Agreement For $15M
22 Oct 2024 //
BUSINESSWIRE
XOMA Royalty Expands Portfolio With 60 Programs From Twist
22 Oct 2024 //
GLOBENEWSWIRE
XOMA Royalty Declares Quarterly Preferred Stock Dividends
23 Sep 2024 //
GLOBENEWSWIRE
XOMA Royalty to Present at Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
XOMA To Present At H.C. Wainwright BioConnect NASDAQ Conference
14 May 2024 //
GLOBENEWSWIRE
XOMA Q1 2024 Financials And Recent Activities
09 May 2024 //
GLOBENEWSWIRE
Daré`s royalty deal; Qlaris Bio raises $24M
30 Apr 2024 //
ENDPTS
XOMA Earns $9M As FDA Approves Day One`s Tovorafenib For pLGG
25 Apr 2024 //
GLOBENEWSWIRE
XOMA Enters into Agreement to Acquire Kinnate Biopharma
16 Feb 2024 //
GLOBENEWSWIRE
XOMA Expands its Royalty and Milestone Portfolio with DSUVIA® Acquisition
18 Jan 2024 //
GLOBENEWSWIRE
XOMA Announces Stock Repurchase Program of up to $50 Million
02 Jan 2024 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
25 Sep 2023 //
GLOBENEWSWIRE
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
XOMA Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
XOMA Added to the Russell 2000® and Russell 3000® Indexes
23 Jun 2023 //
GLOBENEWSWIRE
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
23 Jun 2023 //
PHARMAFILE
XOMA Reports1Q 2023 FYR and Provides Update on the Acceleration
09 May 2023 //
GLOBENEWSWIRE
XOMA to Present at H.C. Wainwright BioConnect Investor Conference
26 Apr 2023 //
GLOBENEWSWIRE
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
30 Mar 2023 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
21 Mar 2023 //
GLOBENEWSWIRE
XOMA Reports Full-Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
XOMA to Present at 43rd Annual Cowen Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
XOMA Acquires Royalty and Milestone License to Ebopiprant
22 Nov 2022 //
GLOBENEWSWIRE
XOMA Reports 3Q FYR and Highlights Recent Operational Events
03 Nov 2022 //
GLOBENEWSWIRE
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 Sep 2022 //
GLOBENEWSWIRE
XOMA Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividend
20 Jun 2022 //
PRESS RELEASE
XOMA Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
21 Mar 2022 //
GLOBENEWSWIRE
XOMA to Present at Oppenheimer`s 32nd Annual Healthcare Conference
10 Mar 2022 //
GLOBENEWSWIRE
XOMA Reports FY 2021 Financial Results and Highlights Recent Operational Events
08 Mar 2022 //
GLOBENEWSWIRE
XOMA to Present at the 42nd Annual Cowen Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
XOMA to Present at Upcoming Investor Conferences
21 Dec 2021 //
GLOBENEWSWIRE
XOMA Earns $35M Milestone Payment as Anti-TGF? Ab Enters Phase 3 Clinical Study
04 Nov 2021 //
GLOBENEWSWIRE
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conf
22 Sep 2021 //
GLOBENEWSWIRE
XOMA Announces Heather L. Franklin Joins its Board of Directors
10 Aug 2021 //
GLOBENEWSWIRE
XOMA Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
U.S. FDA Granted Orphan Drug Designation XOMA’s anti-TGFβ Asset NIS793
28 Jul 2021 //
GLOBENEWSWIRE
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod
15 Jul 2021 //
GLOBE NEWSWIRE
XOMA Declares Quarterly Preferred Stock Dividends
21 Jun 2021 //
GLOBENEWSWIRE
XOMA Prices $35 Million Offering of Depositary Shares
06 Apr 2021 //
GLOBENEWSWIRE
XOMA Announces Offering of Depositary Shares and Series B Cumulative
05 Apr 2021 //
BIOSPACE
Viracta and XOMA Announce Multi-License Milestone and Royalty
23 Mar 2021 //
PRNEWSWIRE
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization
23 Mar 2021 //
BIOSPACE
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering
21 Dec 2020 //
GLOBENEWSWIRE
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual
10 Dec 2020 //
GLOBENEWSWIRE
XOMA Earns $2M Takeda Milestone
17 Nov 2020 //
CONTRACTPHARMA
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports
05 Nov 2020 //
GLOBENEWSWIRE
XOMA Acquires Royalty Interest Four Lysosomal Storage Disorder Enzymes Developed
03 Nov 2020 //
BIOSPACE
XOMA Earns $25 M Milestone Payment as Anti-TGF? Antibody Enters Ph2 Study
28 Oct 2020 //
GLOBENEWSWIRE
XOMA Announces Natasha Hernday Joins its Board of Directors
01 Jul 2020 //
GLOBENEWSWIRE
Xoma: A Lower Risk Way Of Investing In Biotech
10 Nov 2017 //
FORBES
Novartis AG Pays $31 Million+ for XOMA Failed Phase III Drug
26 Aug 2017 //
BIOSPACE
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
25 Aug 2017 //
ENDPTS
Xoma up on broadly positive data, but questions remain
01 Feb 2017 //
FIERCE BIOTECH
10 Major Pharma and FDA Catalysts Coming in December
05 Dec 2016 //
24/7 WALL ST
Embattled Bay Area XOMA Terminates Gevokizumab Trials
11 Mar 2016 //
BIOSPACE
Strike 3: Struggling Xoma jettisons its lead drug after (another) PhIII failure
10 Mar 2016 //
FIERCE BIOTECH
Agenus Acquires PhosImmune in $44.9 Million Deal
29 Dec 2015 //
BIOSPACE
